Will be interesting to hear Ian and Andrews views on why there...

Will be interesting to hear Ian and Andrews views on why there seems to be a resistance to uptake. They must by now have approached a lot of labs and been given reasony why the labs have said "no thanks".

Bct solves a problem that labs dont perceive.
Labs will still need hard copy backup, so why bother.
Too hard to intergrate into existing tracking system.
Product not fit for purpose.
Too expensive.
Cost benifit analysis does not justify the expense and implementation.
Concerns over whether the company will survive.

After the Labcon issue and the resultant crash in the SP, companies figure they can wait it out and pick up BCT in a fire sale.

Given that the board have a lot of skin in the game it is hard to see how this situation has arisen.
Just targeting hi value applications at the expense of other areas was the wrong sales strategy?
What ever the reason, it is hard not to feel we have been groomed to accept a huge loss. There is little appetite among investors for any more CRs, and at the current SP raising more than pocket money will cause massive dilution. The death spiral continues with seemingly nothing to arrest it.